

ASX Market Announcements
ASX Limited
Level 4
North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

RE: Release of Restricted Securities from Escrow

In connection with the quotation of Adherium Limited's fully paid ordinary shares (**Shares**) on the Australian Securities Exchange (**ASX**) on 26 August 2015 certain security holders in the Company were required to enter into ASX imposed restriction agreements and/or voluntary escrow agreements. These agreements restricted the relevant security holders from dealing in their securities for periods of up to 24 months from the date of quotation.

In accordance with ASX Listing Rule 3.10A, the Company advises that 241,314 fully paid ordinary shares of the Company will be released from ASX imposed restriction on 17 August 2016.

Application for quotation of these 241,314 fully paid ordinary shares will also be made following their release from restriction.

Kind regards



Rob Turnbull
CFO & Joint Company Secretary

[ASX: ADR](#)

ABN

24 605 352 510

Company Overview

Adherium is a global leader in digital health technologies which address sub optimal medication use in chronic disease.

Directors

Dr J Doug Wilson (Chair)
Mr Garth Sutherland (Group CEO)
Prof John Mills
Mr Jeremy Curnock Cook
Mr Bruce McHarrie
Mr Bryan Mogridge
Dr Bill Hunter

Joint Company Secretaries

Mr Rob Turnbull
Mr Mark Licciardo

Registered Office

BDO
L14, 140 William Street
Melbourne
Australia

NZ Office

Level 2, 204 Quay Street
Auckland 1010
New Zealand

Email

investors@adherium.com

Websites

www.adherium.com
www.smartinaler.com